|Bid||12.92 x 1100|
|Ask||13.33 x 1300|
|Day's Range||12.01 - 13.45|
|52 Week Range||9.83 - 20.50|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:
It's now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Joining me on the call this afternoon are Peter Greenleaf, President and CEO of Aurinia; Neil Solomons, our Chief Medical Officer; Max Colao, Chief Commercial Officer; and Joe Miller, our Chief Financial Officer.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars.